Sight Sciences, Inc. (SGHT) AI Stock Analysis

Sight Sciences, Inc. is an ophthalmic medical device company dedicated to developing innovative surgical and nonsurgical technologies for eye diseases. Its flagship offering is the OMNI Surgical System, a therapeutic device utilized by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients. The company has also introduced the TearCare System, a wearable eyelid technology designed for the treatment of dry eye disease. Headquartered in Menlo Park, California, and founded in 2010, Sight Sciences distributes its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals across the United States.

Sight Sciences delivered a 5-year revenue CAGR of 22.9% from FY2020 to FY2025, but experienced top-line declines in recent fiscal years. Revenue fell 1.5% in FY2024 to $79.9M and decreased 3.1% in FY2025 to $77.4M. Despite slower sales, gross margin widened from 82.4% in FY2021 to 86.2% in FY2025. Operating margin improved from -105.2% in FY2021 to -48.0% in FY2025, and net loss narrowed from -$63.0M to -$38.4M over the same period. For the trailing twelve months, revenue reached $83.4M with a net profit margin of -35.7%, supported by 19.5% year-over-year revenue growth in the quarter ended June 30, 2026.

As of June 30, 2026, Sight Sciences held $79.8M in cash and short-term investments against $42.0M in total debt, resulting in net cash of $37.8M. The company reported a current ratio of 4.95, total assets of $104.9M, and shareholders' equity of $52.9M, translating to a debt-to-equity ratio of 0.79. Cash generation remains negative, with an operating cash flow of -$29.7M and free cash flow of -$29.9M in FY2025. Capital expenditures totaled $224,000 in FY2025, while the 5-year share count increased by 15.0%.

At a share price of $8.28, Sight Sciences has a market capitalization of $456.1M and an enterprise value of $431.0M. The stock trades at a price-to-sales multiple of 5.5x and an enterprise-value-to-revenue ratio of 5.2x, both above the median of its US-listed Healthcare peers price-to-sales multiple of 4.1x. Its price-to-book ratio is 8.9x. Over the past year, SGHT returned 140.0%, outperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year span, however, the stock declined 61.5% compared to an 83.0% gain for the index.

Wall Street coverage includes 4 Strong Buy, 1 Buy, and 2 Hold recommendations, with no Sell or Strong Sell ratings. The mean price target is $10.17, representing 22.8% upside relative to the last close of $8.28. Consensus estimates project FY2026 revenue of $90.3M and an EPS of -$0.49, reflecting a 38.0% improvement in earnings. For FY2027, 6 analysts anticipate revenue of $101.0M and an EPS of -$0.40. Sight Sciences beat EPS estimates in 3 of the last 4 quarters, with its next earnings release scheduled for November 5, 2026.

This page is an AI-written research summary of Sight Sciences, Inc. (SGHT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SGHT income statement, SGHT balance sheet, SGHT key metrics, SGHT analyst forecast, SGHT chart. See the SGHT stock overview for the latest quote and news.